NovaBay's license and collaboration revenue for the year ended December 31, 2010 decreased to $9.8 million compared to $15.7 million a year ago. License and collaboration revenues for the fourth quarter ended December 31, 2010 decreased to $3.0 million from $7.5 million in the fourth quarter of 2009. This decrease was due to milestone payments of $3.75 million from Galderma S.A. received in the fourth quarter of 2009 and $1.0 million from Alcon received the in first quarter of 2009, which were not repeated in 2010 and the amortization of our upfront payments from Galderma and Alcon ending during 2010.Net loss for 2010 was $4.3 million, compared with a net income in 2009 of $2.7 million. NovaBay reported net income of $161,000 or $.01 cents per diluted share for the fourth quarter, compared with a net income of $3.4 million or $.14 cents per share in the same quarter a year ago. This change was primarily a result of the revenues changes noted above.
NovaBay Pharmaceuticals Provides Fourth Quarter And Full Year 2010 Financial Results And Business Unit Updates
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.